{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T23:30:44Z","timestamp":1769383844325,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00296-021-04808-4","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T08:09:43Z","timestamp":1614758983000},"page":"1419-1427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9713-8641","authenticated-orcid":false,"given":"C. A.","family":"Pereda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. B.","family":"Nishishinya-Aquino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Brito-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"D\u00edaz del Campo Fontecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Rua-Figueroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"4808_CR1","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMra032588","volume":"350","author":"C Thomas","year":"2004","unstructured":"Thomas C, Limper A (2004) Pneumocystis pneumonia. N Engl J Med 350:2487\u20132498","journal-title":"N Engl J Med"},{"issue":"5","key":"4808_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","volume":"77","author":"JW Park","year":"2018","unstructured":"Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB (2018) Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 77(5):644\u2013649","journal-title":"Ann Rheum Dis"},{"key":"4808_CR3","doi-asserted-by":"publisher","first-page":"415810","DOI":"10.1155\/2013\/415810","volume":"2013","author":"R Senanayake","year":"2013","unstructured":"Senanayake R, Mukhtar M (2013) Cotrimoxazole-induced hypoglycaemia in a patient with churg-strauss syndrome. Endocrinology. 2013:415810. https:\/\/doi.org\/10.1155\/2013\/415810","journal-title":"Endocrinology"},{"key":"4808_CR4","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3899\/jrheum.090843","volume":"37","author":"D Cettomai","year":"2010","unstructured":"Cettomai D, Gelber A, Christopher-Stine L (2010) A survey of rheumatologists\u2019 practice for prescribing pneumocystis prophylaxis. J Rheumatol 37:792\u2013799","journal-title":"J Rheumatol"},{"issue":"336","key":"4808_CR5","first-page":"341","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman D (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 8(336):341","journal-title":"BMJ"},{"key":"4808_CR6","unstructured":"L\u00f3pez de Argumedo M, Reviriego E, Guti\u00e9rrez A, JC B (2017) Actualizaci\u00f3n del Sistema de Trabajo Compartido para Revisiones Sistem\u00e1ticas de la Evidencia Cient\u00edfica y Lectura Cr\u00edtica (Plataforma FLC 3.0). Ministerio de Sanidad, Servicios Sociales e Igualdad Servicio de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias del Pa\u00eds Vasco"},{"key":"4808_CR7","unstructured":"Scottish Intercollegiate Guidelines Network (2011) SIGN 50, a guideline developer\u2019s handbook. Edinburgh: SIGN; 2015 (SIGN publication no. 50). [November 2015]. Available from URL: http:\/\/www.sign.ac.uk"},{"issue":"1","key":"4808_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13075-016-1206-8","volume":"19","author":"M Utsunomiya","year":"2017","unstructured":"Utsunomiya M, Dobashi H, Odani T et al (2017) Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial. Arthritis Res Ther 19(1):7","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"4808_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3999\/jscpt.45.89","volume":"45","author":"T Yamamoto","year":"2014","unstructured":"Yamamoto T, Hasunuma T, Takagi K et al (2014) A feasibility study assessing tolerability of daily versus twice weekly trimethoprim-sulfamethoxazole regimen for prophylaxis against pneumocystis pneumonia in patients with systemic autoimmune diseases on glucocorticoid therapy. Jpn J Clin Pharmacol Ther 45(3):89\u201392","journal-title":"Jpn J Clin Pharmacol Ther"},{"issue":"1","key":"4808_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3109\/s10165-012-0625-x","volume":"23","author":"R Maezawa","year":"2013","unstructured":"Maezawa R, Kurasawa K, Arai S, Okada H, Owada T, Fukuda T (2013) Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases. Mod Rheumatol 23(1):62\u201370","journal-title":"Mod Rheumatol"},{"issue":"2","key":"4808_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/PL00021707","volume":"15","author":"J Ogawa","year":"2005","unstructured":"Ogawa J, Harigai M, Nagasaka K, Nakamura T, Miyasaka N (2005) Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. Mod Rheumatol 15(2):91\u201396","journal-title":"Mod Rheumatol"},{"key":"4808_CR12","doi-asserted-by":"publisher","unstructured":"Schmajuk G, Jafri K, Evans M, et al (2018) Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. Semin Arthritis Rheum 48(6):1087\u20131092. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.10.018","DOI":"10.1016\/j.semarthrit.2018.10.018"},{"issue":"4","key":"4808_CR13","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3109\/s10165-012-0730-x","volume":"23","author":"K Takenaka","year":"2013","unstructured":"Takenaka K, Komiya Y, Ota M, Yamazaki H, Nagasaka K (2013) A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases. Mod Rheumatol 23(4):752\u2013758","journal-title":"Mod Rheumatol"},{"issue":"3","key":"4808_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.semarthrit.2011.05.004","volume":"41","author":"P Vananuvat","year":"2011","unstructured":"Vananuvat P, Suwannalai P, Sungkanuparph S, Limsuwan T, Ngamjanyaporn P, Janwityanujit S (2011) Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 41(3):497\u2013502","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"4808_CR15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1445-5994.2007.01382.x","volume":"37","author":"K Meuli","year":"2007","unstructured":"Meuli K, Chapman P, O\u2019Donnell J, Frampton C, Stamp L (2007) Audit of pneumocystis pneumonia in patients seen by the Christchurch Hospital rheumatology service over a 5-year period. Intern Med J 37(10):687\u2013692","journal-title":"Intern Med J"},{"key":"4808_CR16","doi-asserted-by":"publisher","unstructured":"Braga BP, Prieto-Gonzalez S, Hernandez-Rodriguez J (2019) Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases. Med Clin (Barc) 152(12):502\u2013507. https:\/\/doi.org\/10.1016\/j.medcli.2019.01.010","DOI":"10.1016\/j.medcli.2019.01.010"},{"issue":"2","key":"4808_CR17","first-page":"246","volume":"21","author":"B Godeau","year":"1994","unstructured":"Godeau B, Coutant-Perronne V, Le Thi HD et al (1994) Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 21(2):246\u2013251","journal-title":"J Rheumatol"},{"issue":"6","key":"4808_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.2310\/7750.2009.09010","volume":"13","author":"P Grewal","year":"2009","unstructured":"Grewal P, Brassard A (2009) Fact or fiction: does the non-HIV\/AIDS immunosuppressed patient need Pneumocystis jiroveci pneumonia prophylaxis? An updated literature review. J Cutan Med Surg 13(6):308\u2013312","journal-title":"J Cutan Med Surg"},{"issue":"1350","key":"4808_CR19","first-page":"1363","volume":"44","author":"L Cooley","year":"2014","unstructured":"Cooley L, Dendle D, Wolf J, Teh BW, Chen SC, Boultis C (2014) Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies. Int Med J 44(1350):1363","journal-title":"Int Med J"},{"issue":"3","key":"4808_CR20","first-page":"490","volume":"36","author":"G Baulier","year":"2018","unstructured":"Baulier G, Issa N, Gabriel F, Accoceberry I, Camou F, Duffau P (2018) Guidelines for prophylaxis of Pneumocystis pneumonia cannot rely solely on CD4-cell count in autoimmune and inflammatory diseases. Clin Exp Rheumatol 36(3):490\u2013493","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"4808_CR21","first-page":"85","volume":"73","author":"Y Abe","year":"2019","unstructured":"Abe Y, Fujibayashi K, Nishizaki Y et al (2019) Conventional-dose versus half-dose sulfamethoxazole-trimethoprim for the prophylaxis of pneumocystis pneumonia in patients with systemic rheumatic disease: a non-blind. Randomized Controlled Trial Acta Med Okayama 73(1):85\u201389","journal-title":"Randomized Controlled Trial Acta Med Okayama"},{"issue":"7","key":"4808_CR22","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s10067-018-4155-6","volume":"37","author":"EH Matraiah","year":"2018","unstructured":"Matraiah EH, Olisaka N, Philipos M et al (2018) Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis. Clin Rheumatol 37(7):1991\u20131996","journal-title":"Clin Rheumatol"},{"key":"4808_CR23","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","volume":"42","author":"M Ward","year":"1999","unstructured":"Ward M, Donald F (1999) Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 42:780\u2013789","journal-title":"Arthritis Rheum"},{"issue":"3 Pt 1","key":"4808_CR24","first-page":"795","volume":"151","author":"FP Ognibene","year":"1995","unstructured":"Ognibene FP, Shelhamer JH, Hoffman GS et al (1995) Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener\u2019s granulomatosis. Am J Respir Crit Care Med 151(3 Pt 1):795\u2013799","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"4808_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.semarthrit.2015.01.007","volume":"45","author":"AJ Teichtahl","year":"2015","unstructured":"Teichtahl AJ, Morrisroe K, Ciciriello S, Jennens I, Tadros S, Wicks I (2015) Pneumocystis jirovecci pneumonia in connective tissue diseases: comparison with other immunocompromised patients. Semin Arthritis Rheum 45(1):86\u201390","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"4808_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11926-016-0572-1","volume":"18","author":"S Vallabhaneni","year":"2016","unstructured":"Vallabhaneni S, Chiller TM (2016) Fungal infections and new biologic therapies. Curr Rheumatol Rep 18(5):29","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"4808_CR27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/eci.12410","volume":"45","author":"A Kronbichler","year":"2015","unstructured":"Kronbichler A, Jayne DR, Mayer G (2015) Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest 45(3):346\u2013368","journal-title":"Eur J Clin Invest"},{"issue":"132","key":"4808_CR28","first-page":"140","volume":"83","author":"S Tasaka","year":"2020","unstructured":"Tasaka S (2020) Recent advances in the diagnosis and management of Pneumocystis pneumonia. Tuberc Respir Dis. 83(132):140","journal-title":"Tuberc Respir Dis."},{"issue":"2","key":"4808_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jpeds.2013.10.021","volume":"164","author":"D Caselli","year":"2014","unstructured":"Caselli D, Petris MG, Rondelli R et al (2014) Single-day trimethoprim\/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. J Pediatr 164(2):389-392.e381","journal-title":"J Pediatr"},{"key":"4808_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12879-019-3944-0","volume":"19","author":"GV Ramesh Prasad","year":"2019","unstructured":"Ramesh Prasad GV, Beckley J, Mathur M, Gunasekaran M, Nash MM, Rapi L (2019) Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation. BMC Infect Dis 19:311","journal-title":"BMC Infect Dis"},{"key":"4808_CR31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/ajt.12119","volume":"13","author":"SL Martin","year":"2013","unstructured":"Martin SL, Fishman JA (2013) Practice. aTAidCo. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant 13:272\u2013279","journal-title":"Am J Transplant"},{"issue":"6","key":"4808_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11926-017-0664-6","volume":"19","author":"RM Wolfe","year":"2017","unstructured":"Wolfe RM, Peacock JE Jr (2017) Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented? Curr Rheumatol Rep 19(6):35","journal-title":"Curr Rheumatol Rep"},{"issue":"8","key":"4808_CR33","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1002\/1529-0131(200008)43:8<1841::AID-ANR21>3.0.CO;2-Q","volume":"43","author":"JB Chung","year":"2000","unstructured":"Chung JB, Armstrong K, Schwartz JS, Albert D (2000) Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner\u2019s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 43(8):1841\u20131848","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4808_CR34","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1186\/ar2134","volume":"9","author":"M Soejima","year":"2007","unstructured":"Soejima M, Sugiura T, Kawaguchi Y et al (2007) Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res Ther 9(2):R23","journal-title":"Arthritis Res Ther"},{"key":"4808_CR35","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1086\/516993","volume":"25","author":"CL Smith","year":"1997","unstructured":"Smith CL, Brown I (1997) BM Torraca (1997) Acetylator status and tolerance of high-dose trimethoprim\u2013sulfamethoxazole therapy among patients infected with human immunodeficiency virus. Clin Infect Dis. 25:1477\u20131478","journal-title":"Clin Infect Dis."},{"issue":"355","key":"4808_CR36","first-page":"358","volume":"76","author":"J Belchi-Hernandez","year":"1996","unstructured":"Belchi-Hernandez J, Espinosa-Parrra FJ (1996) Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection. Ann Allergy Asthma Immunol 76(355):358","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"265","key":"4808_CR37","first-page":"269","volume":"19","author":"M Petri","year":"1992","unstructured":"Petri M, Allbritton J (1992) Antibiotic allergy in systemic lupus erythematosus: a case\u2013control study. J Rheumatol 19(265):269","journal-title":"J Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04808-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04808-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04808-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T09:32:46Z","timestamp":1697967166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04808-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4808"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04808-4","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,3]]},"assertion":[{"value":"30 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors declare no conflicts of interest<b>.<\/b>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}